Stonebrook Private Inc. Acquires 838 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Stonebrook Private Inc. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 25.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 4,177 shares of the medical research company’s stock after purchasing an additional 838 shares during the period. Stonebrook Private Inc.’s holdings in IQVIA were worth $883,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Versant Capital Management Inc boosted its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in IQVIA in the second quarter valued at about $27,000. Rise Advisors LLC purchased a new stake in shares of IQVIA during the first quarter worth about $31,000. Riverview Trust Co purchased a new position in shares of IQVIA in the 1st quarter valued at approximately $32,000. Finally, International Assets Investment Management LLC acquired a new stake in IQVIA in the 2nd quarter worth approximately $32,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

NYSE IQV traded down $5.07 on Friday, hitting $243.07. The company had a trading volume of 919,808 shares, compared to its average volume of 1,056,622. The company’s fifty day moving average price is $234.92 and its 200-day moving average price is $234.63. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a market capitalization of $44.29 billion, a PE ratio of 33.21, a PEG ratio of 2.37 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same period last year, the company posted $2.22 EPS. The business’s revenue was up 2.3% on a year-over-year basis. As a group, analysts predict that IQVIA Holdings Inc. will post 10.24 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on IQV. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price target for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. The Goldman Sachs Group began coverage on IQVIA in a research note on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Barclays raised their price objective on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Argus upgraded IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $266.67.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.